| Literature DB >> 32024801 |
Yanxia Chen1, Aubin Moutal1, Edita Navratilova1, Caroline Kopruszinski1, Xu Yue1, Megumi Ikegami1, Michele Chow1, Iori Kanazawa1, Shreya Sai Bellampalli1, Jennifer Xie1, Amol Patwardhan1, Kenner Rice2, Howard Fields3, Armen Akopian4, Volker Neugebauer5, David Dodick6, Rajesh Khanna1, Frank Porreca7,6.
Abstract
Pain is more prevalent in women for reasons that remain unclear. We have identified a mechanism of injury-free nociceptor sensitization and opioid-induced hyperalgesia (OIH) promoted by prolactin (PRL) in females. PRL signals through mutually inhibitory long (PRLR-L) and short (PRLR-S) receptor isoforms, and PRLR-S activation induces neuronal excitability. PRL and PRLR expression were higher in females. CRISPR-mediated editing of PRLR-L promoted nociceptor sensitization and allodynia in naïve, uninjured female mice that depended on circulating PRL. Opioids, but not trauma-induced nerve injury, decreased PRLR-L promoting OIH through activation of PRLR-S in female mice. Deletion of both PRLR-L and PRLR-S (total PRLR) prevented, whereas PRLR-L overexpression rescued established OIH selectively in females. Inhibition of circulating PRL with cabergoline, a dopamine D2 agonist, up-regulated PRLR-L and prevented OIH only in females. The PRLR-L isoform therefore confers protection against PRL-promoted pain in females. Limiting PRL/PRLR-S signaling pharmacologically or with gene therapies targeting the PRLR may be effective for reducing pain in a female-selective manner.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32024801 PMCID: PMC7523341 DOI: 10.1126/scitranslmed.aay7550
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956